MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines

Cancer Biology and Therapy

Volumn 14, Issue 10, 2013, Pages 932-936

  Almhanna, Khaldoun ^a   Cubitt, Christopher L ^a   Zhang, Shumin ^a   Kazim, Sabiha ^a   Husain, Kazim ^a   Sullivan, Dan ^a   Sebti, Said ^a   Malafa, Mokenge ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Carboplatinum; Gastric cancer; MK 2206; Paclitaxel

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CARBOPLATIN; PACLITAXEL; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; LABORATORY DEVICE; STOMACH CANCER; WESTERN BLOTTING;

CARBOPLATINUM; GASTRIC CANCER; MK-2206; PACLITAXEL;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; STOMACH NEOPLASMS;

EID: 84885207640     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25939     Document Type: Article

References (15)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
2. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, et al.; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24:4991-7; PMID:17075117; http://dx.doi.org/10.1200/JCO.2006.06.8429 (Pubitemid 46631401)
3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687-97; PMID:20728210; http://dx.doi. org/10.1016/S0140-6736(10)61121-X
4. Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res 2011; 31:4387-92; PMID:22199303
5. Yang ZZ, Tschopp O, Baudry A, Dümmler B, Hynx D, Hemmings BA. Physiological functions of protein kinase B/Akt. Biochem Soc Trans 2004; 32:350-4; PMID:15046607; http://dx.doi.org/10.1042/BST0320350 (Pubitemid 38582126)
6. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94:29-86; PMID:16095999; http://dx.doi.org/10.1016/S0065-230X(05)94002-5 (Pubitemid 41202364)
7. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001; 15:2203-8; PMID:11544177; http://dx.doi.org/10.1101/gad.913901 (Pubitemid 32843832)
8. rd, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001; 292:1728-31; PMID:11387480; http://dx.doi. org/10.1126/science.292.5522.1728 (Pubitemid 32506248)
9. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 2005; 25:1869-78; PMID:15713641; http://dx.doi.org/10.1128/MCB.25.5.1869-1878.2005 (Pubitemid 40280150)
10. Nam SY, Lee HS, Jung GA, Choi J, Cho SJ, Kim MK, Kim WH, Lee BL. Akt/PKB activation in gastric carcinomas correlates with clinico-pathologic variables and prognosis. APMIS 2003; 111:1105-13; PMID:14678019; http://dx.doi. org/10.1111/j.1600-0463.2003.apm1111205.x (Pubitemid 38091249)
11. Cinti C, Vindigni C, Zamparelli A, La Sala D, Epistolato MC, Marrelli D, Cevenini G, Tosi P. Activated Akt as an indicator of prognosis in gastric cancer. Virchows Arch 2008; 453:449-55; PMID:18841391; http://dx.doi.org/10. 1007/s00428-008-0676-8
12. Yang S, Ngo VC, Lew GB, Chong LW, Lee SS, Ong WJ, Lam WL, Thng CH, Koong HN, Ong HS, et al. AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther 2009; 8:2537-45; PMID:19723882; http://dx.doi.org/10.1158/1535-7163.MCT-09-0213
13. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9:1956-67; PMID:20571069; http://dx.doi.org/10.1158/1535-7163.MCT-09-1012
14. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, Rosen N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008; 3:e3065; PMID:18725974; http://dx.doi.org/10.1371/journal.pone.0003065
15. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70:440-6; PMID:20068163; http://dx.doi. org/10.1158/0008-5472.CAN-09-1947